MedTrace Logo

Cannabinoids in Bipolar Affective Disorder

NCT00397605 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-09-18

No results posted yet for this study

Summary

Some people with bipolar disorder who use cannabis (marijuana) claim that it eases the symptoms of depression and mania. There are many chemicals (called cannabinoids) found in cannabis but two particular ones appear to have medicinal (therapeutic) effects. These two compounds are: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). These cannabinoids appear to have mood, anxiety, and sedative effects as well as have antipsychotic and anticonvulsant properties. This study will try to find out if these cannabinoids can be of benefit as an add-on treatment in bipolar disorder and what effects it has on thinking power and memory.

Conditions

  • Bipolar Affective Disorder

Interventions

DRUG

Synthetic cannabinoids (1:1 ratio of THC % CBD)

Randomized crossover study of 2 weeks of active study medication (maximum daily dosage of 60 mg) vs. 2 weeks of matching placebo.

Sponsors & Collaborators

  • Vancouver General Hospital

    collaborator OTHER

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Allan H. Young, Ph.D · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00397605 on ClinicalTrials.gov